No effect of human chorionic gonadotropin treatment due to threatened abortion in early pregnancy for birth outcomes

• Authors: Andrew Czeizel , István Dudás , János Gidai , Erzsébet Horváth-Puhó
• Languages of publication: EN

Abstracts

EN

Human chorionic gonadotropin (HCG) is used parenterally for treatment of threatened abortions and repeated spontaneous abortion in pregnant women. No controlled epidemiological studies of preterm birth and low birthweight newborns in pregnant women with HCG treatment have been published while the results of animal investigations were controversial. The data of 97 pregnant women with HCG treatment in the second and third months of pregnancy due to threatened abortion and/or previous spontaneous abortion(s) was compared with the data of other 38,054 pregnant women in the population-based large data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities. There was no difference in mean gestational age at delivery and birth weight, in addition the rate of preterm birth and low birthweight newborns. Parenteral HCG treatment in the early pregnancy due to threatened abortion did not associate with a higher risk for preterm births or low birthweight newborns. However, a higher occurrence of gestational diabetes was found in pregnant women with HCG treatment and there was a slight male excess among newborn infants (p=0.06).

Keywords

EN

Human chorionic gonadotropin; Pregnancy; Threatened abortion; Preterm birth; Low birthweight newborns

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2008
• Volume: 3
• Issue: 1
• Pages: 71-76

Dates

published

1 - 3 - 2008

online

1 - 3 - 2008

Contributors

author

Andrew Czeizel

• Foundation for the Community Control of Hereditary Diseases, 3H-1148, Budapest, Hungary

author

István Dudás

• Foundation for the Community Control of Hereditary Diseases, 3H-1148, Budapest, Hungary

author

János Gidai

• Foundation for the Community Control of Hereditary Diseases, 3H-1148, Budapest, Hungary

author

Erzsébet Horváth-Puhó

• Foundation for the Community Control of Hereditary Diseases, 3H-1148, Budapest, Hungary

References

• [1] Conlson C.J., Molecular mechanism of drug action. Taylor and Francis, London. 1988
• [2] Sakai N., Endo A., Potential teratogenicity of gonadotropin treatment for ovulation induction in the mouse offspring. Teratology, 1987, 36, 229–233 http://dx.doi.org/10.1002/tera.1420360211[Crossref]
• [3] Bussi R., Ciampolillo C., Commotto L., Komatsu S., Maraschin R., Reproductive and developmental toxicity studies of SJ-0021 (v-hFSH). Yakuri to Chiryo., 1995, 23, 1953–1997 cit. Shepard TH, and Lemire RJ, 2004.
• [4] Hultquist G.T., Engfeldt B., Growth of rat fetuses produced experimentally by means of administration of hormones to the mother during pregnancy. Acta Endocrinol (Kbh), 1949, 3, 365–376
• [5] Hack M., Brish M., Serr D., Insler V., Lunenfeld B., Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after gonadotropin therapy. J.A.M.A., 1970, 211, 791–793 http://dx.doi.org/10.1001/jama.211.5.791[Crossref]
• [6] Ben-Rafael Z., Mashiach S., Velsner G., Farine D., Lunenfeld B., Serr D.M., Spontaneous pregnancy and its outcome after human menopausal gonadotropin/human chorionic gonadotropin-induced pregnancy. Fertil. Steril., 1981, 36, 560–566
• [7] Ben-Rafael Z., Dor J., Mashiach S., Blankstein J., Lunenfeld B., Serr D.M., Abortion rate in pregnancies following ovulation induced by human menopausal gonadotropin/human chorionic gonadotropin. Fertil. Steril., 1983, 39, 157–162
• [8] Caspi E., Ronen J., Schreyer P., Goldberg M.D., The outcome of pregnancy after gonadotrophin therapy. Br. J. Obstet. Gynecol., 1996, 83, 967–973
• [9] Shepard T.H., Lemire R.J., Catalog of Teratogenic Agents. 11th ed. John Hopkins. Univ. Press, Baltimore, 2004
• [10] Czeizel A.E., Rockenbauer M., Siffel Cs., Varga E., Description and mission evaluation of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980–1996. Teratology, 2001, 63, 176–185 http://dx.doi.org/10.1002/tera.1032[Crossref]
• [11] Czeizel A.E., The first 25 years of the Hungarian Congenital Abnormality Registry. Teratology, 1997, 55, 299–305 http://dx.doi.org/10.1002/(SICI)1096-9926(199705)55:5<299::AID-TERA1>3.0.CO;2-V[Crossref]
• [12] Czeizel A.E., Petik D., Vargha P., Validation studies of drug exposures in pregnant women. Pharmacoepidemiol. Drug Safety, 2003, 12, 409–406 http://dx.doi.org/10.1002/pds.766[Crossref]
• [13] Czeizel A.E., Petik D., Puho E., Smoking and alcohol drinking during pregnancy: the validity of retrospective maternal self-reported information. Cent. Eur. J. Publ. Hlth., 2004, 12, 179–193
• [14] Czeizel A.E., Puhó E., Maternal use of nutritional supplements during the first month of pregnancy and decreased risk of Down’s syndrome: casecontrol study. Nutrition, 2005, 21, 698–704 http://dx.doi.org/10.1016/j.nut.2004.10.017[Crossref]

Identifiers

DOI

10.2478/s11536-007-0056-9